Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis

Next Previous
X
Search
Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 15 Dec 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenabasum (Primary)
  • Indications Dermatomyositis
  • Focus Registrational; Therapeutic Use
  • Acronyms DETERMINE
  • Sponsors Corbus Pharmaceuticals

    • Most Recent Events

    • 01 Dec 2023 Results assessing the sensitivity of Cutaneous Dermatomyositis Disease Area and Severity Index Activity score, Cutaneous Dermatomyositis Activity Investigator Global Assessment, Total Improvement Score, and other outcome measures to detect improvement in DM skin disease activity published in the Journal of Investigative Dermatology
    • 15 Nov 2023 Results assessing a new composite outcome measure, the Dermatomyositis Outcomes for Muscle and Skin (DMOMS), presented at the ACR Convergence 2023.
    • 14 Nov 2022 Results assessing Safety Efficacy and Safety of Lenabasum in the Phase 3 DeterMine Trial in Dermatomyositis presented at the ACR Convergence 2022

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top